
|Articles|January 9, 2006
R.Ph.s give thumbs-down to Rx-to-OTC switch of Xenical
Advertisement
The majority of pharmacists are not in favor of an Rx-to-OTC switch of Roche’s antiobesity drug Xenical (orlistat), judging from the results of a recent Instant Poll on Drug Topics’ Web site. To the question “Should a weaker-strength version of Xenical be approved over the counter for weight loss?” 63% of the 224 respondents gave a thumbs-down to a switch, 35% voted in favor of it, and about 2% said they don’t know.
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Expert Addresses Pharmacy’s Uncertainty Amid MFN Drug Pricing Policy
2
Q&A: How Complex US Drug Market Impedes MFN Pricing Policy
3
Why Trump’s Second Term Is Different for the MFN Drug Pricing Policy
4
Variation in Insulin Pump Options Creates Opportunity for Pharmacist Counseling | ASHP Midyear 2025
5























































































































